KITLG and neutropenia: Additionally, LMJ729 did not inhibit SCF‐mediated c‐\x8FKit activation, which suggests that target‐mediated adverse events, including neutropenia and reduced hematopoiesis, are minimized as SCF can activate c‐Kit even in the presence of LMJ729.